<p>Tiff Advisory Services LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中披露，其在 The Oncology Institute, Inc.（NASDAQ:TOI - 免費報告）的持股在第四季度減少了 77.2%。該基金在此期間出售了 661,059 股後，持有該公司 195,569 股股票。Oncology Institute 佔 Tiff Advisory Services LLC 投資組合的 0.1%，是其第 19 大持倉。截至其最近的 SEC 報告，Tiff Advisory Services LLC 持有的 Oncology Institute 價值約為 696,000 美元，約佔 0.20%。</p>
<p>獲取 <strong>Oncology Institute</strong> 警報：</p>
<p>其他幾家機構投資者最近也調整了對該公司的持股。Larson Financial Group LLC 在第四季度將其在 Oncology Institute 的持倉增加了 19.7%。Larson Financial Group LLC 目前持有 31,468 股該公司股票，價值 112,000 美元，此前在上個季度又購買了 5,181 股。HighTower Advisors LLC 在第四季度將其在 Oncology Institute 的持倉增加了 5.5%。HighTower Advisors LLC 目前持有 85,851 股該公司股票，價值 306,000 美元，此前在上個季度又購買了 4,489 股。Pekin Hardy Strauss Inc. 在第四季度購買了 Oncology Institute 的新股份，價值 36,000 美元。R Squared Ltd 在第四季度購買了 Oncology Institute 的新股份，價值 41,000 美元。最後，Kingswood Wealth Advisors LLC 在第四季度將其在 Oncology Institute 的持倉增加了 27.2%。Kingswood Wealth Advisors LLC 目前持有 98,700 股該公司股票，價值 351,000 美元，此前在上個季度又購買了 21,100 股。36.86% 的股票由對沖基金和其他機構投資者持有。</p>
<h2>Oncology Institute 股票表現</h2>
<p>NASDAQ:TOI 的股票在週五開盤價為 4.59 美元。該公司的市值為 4.5368 億美元，市盈率為 -12.41，貝塔值為 0.33。該股票的 50 日簡單移動平均線為 3.50 美元，200 日簡單移動平均線為 3.33 美元。The Oncology Institute, Inc. 的 52 周低點為 2.02 美元，52 周高點為 4.88 美元。</p>
<p>Oncology Institute（NASDAQ:TOI - 獲取免費報告）最後一次公佈財報是在 5 月 7 日星期四。該公司報告季度每股收益（EPS）為 -0.02，超出市場共識預期的 -0.07，超出幅度為 0.05 美元。該公司在本季度的收入為 1.4744 億美元，而分析師預期為 1.4210 億美元。整體來看，股票分析師預測 The Oncology Institute, Inc. 在當前財年將發佈 -0.2 的每股收益。</p>
<h2>內部活動</h2>
<p>在相關消息中，主要股東 Jorey Chernett 於 3 月 13 日星期五收購了 263,000 股該公司的股票。該股票的購買均價為每股 2.92 美元，總價值為 767,960.00 美元。完成購買後，該內部人士直接持有 10,115,944 股該公司的股票，價值 29,538,556.48 美元。這代表其持股增加了 2.67%。該購買在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。此外，董事 Mohit Kaushal 於 4 月 14 日星期二出售了 57,286 股該公司的股票。該股票的出售均價為 3.50 美元，總價值為 200,501.00 美元。完成交易後，該董事直接持有 211,016 股該公司的股票，價值 738,556 美元。此交易代表其持倉減少了 21.35%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去九十天內購買了價值 2,038,896 美元的 637,485 股公司股票。公司內部人士持有該公司 8.50% 的股份。</p>
<h2>分析師評級變動</h2>
<p>幾位研究分析師對 TOI 股票發佈了報告。BTIG Research 在 3 月 9 日星期一的研究報告中重申了 “買入” 評級，並對 Oncology Institute 的股票設定了 7.00 美元的目標價。Weiss Ratings 在 4 月 20 日星期一的研究報告中重申了對 Oncology Institute 股票的 “賣出（d-）” 評級。B. Riley Financial 將 Oncology Institute 的目標價從 6.00 美元上調至 8.00 美元，並在 3 月 13 日星期五的研究報告中給予該股票 “買入” 評級。最後，Needham &amp; Company LLC 在 3 月 9 日星期一的研究報告中重申了 “買入” 評級，並對 Oncology Institute 的股票設定了 5.00 美元的目標價。四位股票研究分析師對該股票給予了 “買入” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，Oncology Institute 當前的平均評級為 “適度買入”，平均目標價為 7.00 美元。</p>
<p><strong>獲取我們關於 Oncology Institute 的最新報告</strong></p>
<h2>Oncology Institute 簡介</h2>
<p>（免費報告）</p>
<p>The Oncology Institute, Inc. 是一家腫瘤學公司，在美國提供各種醫學腫瘤學服務。該公司通過三個部門運營：藥房、患者服務和臨牀試驗及其他。它提供醫生服務、內部輸液和藥房、臨牀試驗、放射治療、門診血液產品輸血和患者支持服務，以及教育研討會、支持小組和諮詢服務。該公司還提供管理臨牀試驗、姑息治療項目、幹細胞移植服務以及與非社區基礎的學術和三級護理設置相關的其他護理交付模式；併為一系列製藥和醫療設備公司進行臨牀試驗。</p>
<h2>相關文章</h2>
<ul>
<li>我們更看好的五隻股票，而非腫瘤研究所</li>
<li>Workday 驗證了 AI 飛輪：股價復甦開始</li>
<li>HubSpot 在 2019 年的水平是一個機會——而不是警告</li>
<li>Decker 的雙重超預期是看漲信號——還是僅僅是 HOKA 的把戲？</li>
<li>Kiniksa Pharmaceuticals 在 100% 的反彈後仍有上漲空間</li>
</ul>
<p><strong>想看看其他對腫瘤研究所持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 The Oncology Institute, Inc. (NASDAQ:TOI - 免費報告) 的最新 13F 文件和內部交易。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J"/></p>
<p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1,000 美元在腫瘤研究所嗎？</h2>
<p>在你考慮腫瘤研究所之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而腫瘤研究所並不在名單上。</p>
<p>雖然腫瘤研究所目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>查看這五隻股票</p>

醫藥突破 ETF - ALPS

標普生物技術 3 倍做多 - Direxion

標普生物技術 ETF - SPDR

紐交所高增長板生物技術指數 ETF - First Trust

納斯達克生物科技指數 ETF - iShares Nasdaq

2 倍做多納斯達克生物技術 ETF - ProShares

生物科技 ETF - VanEck Vectors

動態生物技術與基因組 ETF - Invesco

<p>Tiff Advisory Services LLC 在第四季度減少了對 The Oncology Institute, Inc. (NASDAQ:TOI) 的持股比例，降幅為 77.2%，目前持有 195,569 股。其他機構投資者也調整了他們的持倉。該股票開盤價為 4.59 美元，市值為 4.5368 億美元。The Oncology Institute 報告每股收益為（0.02）美元，超出預期。分析師的評級各不相同，目標價格範圍在 5.00 美元到 8.00 美元之間</p>

<p>Tiff Advisory Services LLC cut its holdings in shares of The Oncology Institute, Inc. (NASDAQ:TOI - Free Report) by 77.2% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 195,569 shares of the company's stock after selling 661,059 shares during the period. Oncology Institute makes up 0.1% of Tiff Advisory Services LLC's portfolio, making the stock its 19th biggest position. Tiff Advisory Services LLC owned about 0.20% of Oncology Institute worth $696,000 as of its most recent SEC filing.</p>
<div class="lb-trans"><p>Tiff Advisory Services LLC 在最近向證券交易委員會（SEC）提交的 13F 表格中披露，其在 The Oncology Institute, Inc.（NASDAQ:TOI - 免費報告）的持股在第四季度減少了 77.2%。該基金在此期間出售了 661,059 股後，持有該公司 195,569 股股票。Oncology Institute 佔 Tiff Advisory Services LLC 投資組合的 0.1%，是其第 19 大持倉。截至其最近的 SEC 報告，Tiff Advisory Services LLC 持有的 Oncology Institute 價值約為 696,000 美元，約佔 0.20%。</p>
</div><p>Get <strong>Oncology Institute</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Oncology Institute</strong> 警報：</p>
</div><p>Several other institutional investors also recently modified their holdings of the business. Larson Financial Group LLC boosted its position in shares of Oncology Institute by 19.7% during the fourth quarter. Larson Financial Group LLC now owns 31,468 shares of the company's stock valued at $112,000 after buying an additional 5,181 shares during the last quarter. HighTower Advisors LLC boosted its position in shares of Oncology Institute by 5.5% during the fourth quarter. HighTower Advisors LLC now owns 85,851 shares of the company's stock valued at $306,000 after buying an additional 4,489 shares during the last quarter. Pekin Hardy Strauss Inc. purchased a new stake in shares of Oncology Institute during the fourth quarter valued at $36,000. R Squared Ltd purchased a new stake in shares of Oncology Institute during the fourth quarter valued at $41,000. Finally, Kingswood Wealth Advisors LLC boosted its position in shares of Oncology Institute by 27.2% during the fourth quarter. Kingswood Wealth Advisors LLC now owns 98,700 shares of the company's stock valued at $351,000 after buying an additional 21,100 shares during the last quarter. 36.86% of the stock is owned by hedge funds and other institutional investors.</p>
<div class="lb-trans"><p>其他幾家機構投資者最近也調整了對該公司的持股。Larson Financial Group LLC 在第四季度將其在 Oncology Institute 的持倉增加了 19.7%。Larson Financial Group LLC 目前持有 31,468 股該公司股票，價值 112,000 美元，此前在上個季度又購買了 5,181 股。HighTower Advisors LLC 在第四季度將其在 Oncology Institute 的持倉增加了 5.5%。HighTower Advisors LLC 目前持有 85,851 股該公司股票，價值 306,000 美元，此前在上個季度又購買了 4,489 股。Pekin Hardy Strauss Inc. 在第四季度購買了 Oncology Institute 的新股份，價值 36,000 美元。R Squared Ltd 在第四季度購買了 Oncology Institute 的新股份，價值 41,000 美元。最後，Kingswood Wealth Advisors LLC 在第四季度將其在 Oncology Institute 的持倉增加了 27.2%。Kingswood Wealth Advisors LLC 目前持有 98,700 股該公司股票，價值 351,000 美元，此前在上個季度又購買了 21,100 股。36.86% 的股票由對沖基金和其他機構投資者持有。</p>
</div><h2>Oncology Institute Stock Performance</h2>
<div class="lb-trans"><h2>Oncology Institute 股票表現</h2>
</div><p>Shares of NASDAQ:TOI opened at $4.59 on Friday. The stock has a market capitalization of $453.68 million, a price-to-earnings ratio of -12.41 and a beta of 0.33. The stock's 50-day simple moving average is $3.50 and its two-hundred day simple moving average is $3.33. The Oncology Institute, Inc. has a 52-week low of $2.02 and a 52-week high of $4.88.</p>
<div class="lb-trans"><p>NASDAQ:TOI 的股票在週五開盤價為 4.59 美元。該公司的市值為 4.5368 億美元，市盈率為 -12.41，貝塔值為 0.33。該股票的 50 日簡單移動平均線為 3.50 美元，200 日簡單移動平均線為 3.33 美元。The Oncology Institute, Inc. 的 52 周低點為 2.02 美元，52 周高點為 4.88 美元。</p>
</div><p>Oncology Institute (NASDAQ:TOI - Get Free Report) last announced its earnings results on Thursday, May 7th. The company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.07) by $0.05. The firm had revenue of $147.44 million during the quarter, compared to analysts' expectations of $142.10 million. As a group, equities analysts forecast that The Oncology Institute, Inc. will post -0.2 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Oncology Institute（NASDAQ:TOI - 獲取免費報告）最後一次公佈財報是在 5 月 7 日星期四。該公司報告季度每股收益（EPS）為 -0.02，超出市場共識預期的 -0.07，超出幅度為 0.05 美元。該公司在本季度的收入為 1.4744 億美元，而分析師預期為 1.4210 億美元。整體來看，股票分析師預測 The Oncology Institute, Inc. 在當前財年將發佈 -0.2 的每股收益。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>內部活動</h2>
</div><p>In related news, major shareholder Jorey Chernett acquired 263,000 shares of the firm's stock in a transaction dated Friday, March 13th. The shares were purchased at an average price of $2.92 per share, with a total value of $767,960.00. Following the completion of the purchase, the insider directly owned 10,115,944 shares of the company's stock, valued at $29,538,556.48. This represents a 2.67% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities &amp; Exchange Commission, which is accessible through this hyperlink. Also, Director Mohit Kaushal sold 57,286 shares of the firm's stock in a transaction dated Tuesday, April 14th. The stock was sold at an average price of $3.50, for a total value of $200,501.00. Following the completion of the transaction, the director directly owned 211,016 shares in the company, valued at $738,556. This trade represents a 21.35% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders bought 637,485 shares of company stock worth $2,038,896 in the last ninety days. Corporate insiders own 8.50% of the company's stock.</p>
<div class="lb-trans"><p>在相關消息中，主要股東 Jorey Chernett 於 3 月 13 日星期五收購了 263,000 股該公司的股票。該股票的購買均價為每股 2.92 美元，總價值為 767,960.00 美元。完成購買後，該內部人士直接持有 10,115,944 股該公司的股票，價值 29,538,556.48 美元。這代表其持股增加了 2.67%。該購買在向證券交易委員會提交的文件中披露，相關文件可通過此鏈接訪問。此外，董事 Mohit Kaushal 於 4 月 14 日星期二出售了 57,286 股該公司的股票。該股票的出售均價為 3.50 美元，總價值為 200,501.00 美元。完成交易後，該董事直接持有 211,016 股該公司的股票，價值 738,556 美元。此交易代表其持倉減少了 21.35%。有關此次出售的更多細節可在官方 SEC 披露中找到。該交易是在預先安排的 10b5-1 交易計劃下執行的。內部人士在過去九十天內購買了價值 2,038,896 美元的 637,485 股公司股票。公司內部人士持有該公司 8.50% 的股份。</p>
</div><h2>Analyst Ratings Changes</h2>
<div class="lb-trans"><h2>分析師評級變動</h2>
</div><p>Several research analysts have issued reports on TOI shares. BTIG Research reissued a &#34;buy&#34; rating and issued a $7.00 target price on shares of Oncology Institute in a research report on Monday, March 9th. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Oncology Institute in a research report on Monday, April 20th. B. Riley Financial raised their target price on Oncology Institute from $6.00 to $8.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 13th. Finally, Needham &amp; Company LLC reissued a &#34;buy&#34; rating and issued a $5.00 target price on shares of Oncology Institute in a research report on Monday, March 9th. Four equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, Oncology Institute currently has an average rating of &#34;Moderate Buy&#34; and an average target price of $7.00.</p>
<div class="lb-trans"><p>幾位研究分析師對 TOI 股票發佈了報告。BTIG Research 在 3 月 9 日星期一的研究報告中重申了 “買入” 評級，並對 Oncology Institute 的股票設定了 7.00 美元的目標價。Weiss Ratings 在 4 月 20 日星期一的研究報告中重申了對 Oncology Institute 股票的 “賣出（d-）” 評級。B. Riley Financial 將 Oncology Institute 的目標價從 6.00 美元上調至 8.00 美元，並在 3 月 13 日星期五的研究報告中給予該股票 “買入” 評級。最後，Needham &amp; Company LLC 在 3 月 9 日星期一的研究報告中重申了 “買入” 評級，並對 Oncology Institute 的股票設定了 5.00 美元的目標價。四位股票研究分析師對該股票給予了 “買入” 評級，一位給予了 “賣出” 評級。根據 MarketBeat.com 的數據，Oncology Institute 當前的平均評級為 “適度買入”，平均目標價為 7.00 美元。</p>
</div><p><strong>Get Our Latest Report on Oncology Institute</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 Oncology Institute 的最新報告</strong></p>
</div><h2>Oncology Institute Profile</h2>
<div class="lb-trans"><h2>Oncology Institute 簡介</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免費報告）</p>
</div><p>The Oncology Institute, Inc, an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials &amp; Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies.</p>
<div class="lb-trans"><p>The Oncology Institute, Inc. 是一家腫瘤學公司，在美國提供各種醫學腫瘤學服務。該公司通過三個部門運營：藥房、患者服務和臨牀試驗及其他。它提供醫生服務、內部輸液和藥房、臨牀試驗、放射治療、門診血液產品輸血和患者支持服務，以及教育研討會、支持小組和諮詢服務。該公司還提供管理臨牀試驗、姑息治療項目、幹細胞移植服務以及與非社區基礎的學術和三級護理設置相關的其他護理交付模式；併為一系列製藥和醫療設備公司進行臨牀試驗。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>相關文章</h2>
</div><ul>
<li>Five stocks we like better than Oncology Institute</li>
<li>Workday Validates AI Flywheel: Stock Price Recovery Begins</li>
<li>HubSpot at 2019 Levels Is an Opportunity—Not a Warning</li>
<li>Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus?</li>
<li>Kiniksa Pharmaceuticals Still Has Room to Run After 100% Rally</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更看好的五隻股票，而非腫瘤研究所</li>
<li>Workday 驗證了 AI 飛輪：股價復甦開始</li>
<li>HubSpot 在 2019 年的水平是一個機會——而不是警告</li>
<li>Decker 的雙重超預期是看漲信號——還是僅僅是 HOKA 的把戲？</li>
<li>Kiniksa Pharmaceuticals 在 100% 的反彈後仍有上漲空間</li>
</ul>
</div><p><strong>Want to see what other hedge funds are holding TOI?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for The Oncology Institute, Inc. (NASDAQ:TOI - Free Report).</p>
<div class="lb-trans"><p><strong>想看看其他對腫瘤研究所持有的對沖基金嗎？</strong> 訪問 HoldingsChannel.com 獲取 The Oncology Institute, Inc. (NASDAQ:TOI - 免費報告) 的最新 13F 文件和內部交易。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VE9J" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NASDAQ&amp;Symbol=TOI"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍事科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Oncology Institute Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1,000 美元在腫瘤研究所嗎？</h2>
</div><p>Before you consider Oncology Institute, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮腫瘤研究所之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Oncology Institute wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄建議客户現在購買的股票，以便在更廣泛的市場注意到之前……而腫瘤研究所並不在名單上。</p>
</div><p>While Oncology Institute currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然腫瘤研究所目前在分析師中有中等買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>查看這五隻股票</p>
</div>

Tiff Advisory Services LLC Reduces Position in The Oncology Institute, Inc. $TOI

Market Beat

Oncology Institute

Oncology Institute - CW22

B Riley Financial Pref Share RILYL 7.375 Perp 09/04/25 B

B Riley Financial Pref Share RILYG 7.25 12/21/27

B Riley Financial Pref Share RILYN 6.5 09/30/2026

B Riley Financial Pref Share RILYK 5.5 03/31/26

B. Riley Financial-存託優先股A

B Riley Financial Pref Share RILYZ 5.25 08/31/28

B Riley Financial Pref Share RILYT 6.0 01/31/28

Tiff Advisory Services LLC 減少了在 The Oncology Institute, Inc. 的頭寸 $TOI